When former Tennessee Titans star Chris Johnson announced in early 2025 that he had been diagnosed with amyotrophic lateral sclerosis, the news reverberated far beyond the locker room. Johnson, once celebrated for his breakaway speed, now faces a disease that attacks the nerve cells responsible for muscle control, gradually stripping away the ability to move, speak and even breathe.
His revelation is not an isolated case. A growing body of research indicates that professional football players are far more likely to develop ALS than the general population, a finding that has prompted the NFL to include the condition in its concussion settlement benefits.
Mike Florio, a veteran NFL insider, recently explained on his Pro Football Talk platform that the league’s medical committee has acknowledged the elevated risk, citing a 2021 study that documented ALS incidence four times higher among former players compared to the broader society.
The Link Between Football and Neurodegeneration
The connection between the sport’s physical toll and neurodegenerative disease is not new. Chronic traumatic encephalopathy, or CTE, has long been associated with repeated head impacts, while ALS—often called Lou Gehrig’s disease—has emerged as another silent adversary among gridiron veterans.
Beyond Johnson, other former NFL standouts such as Steve McMichael, Tim Shaw and the late Steve Gleason have publicly disclosed their battles with ALS, underscoring a pattern that transcends individual careers.
The NFL’s concussion settlement, finalized in 2015, originally covered a range of neurocognitive injuries but only later incorporated ALS as a compensable condition after sustained advocacy from former players and advocacy groups.
Medical experts caution that while the exact mechanism linking football hits to ALS remains under investigation, the consensus is clear: the sport’s high‑impact nature poses a significant health hazard, especially when cumulative head trauma is left unchecked.
Efforts to mitigate the risk are gaining momentum. Advances in helmet technology, stricter concussion protocols, and increased funding for ALS research are all part of a broader strategy aimed at protecting current athletes and providing support for those already affected.
A Turning Point for Research
Researchers are accelerating clinical trials that target the underlying protein misfolding responsible for ALS, while advocacy organizations are lobbying for increased federal grants to accelerate drug development. The recent surge in public awareness, sparked by Johnson’s disclosure, is expected to translate into more clinical participation and faster breakthroughs.
Legislators in several states have begun drafting bills that would require enhanced medical monitoring for professional football players, and the NFL Players Association is negotiating new safety clauses that could reshape practice routines and game‑day protocols.
As the conversation evolves, the story of Chris Johnson serves as both a personal tragedy and a catalyst for systemic change, reminding fans, officials and policymakers that the game’s excitement must be balanced against the long‑term wellbeing of those who play it.